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Bethesda, MarylandWhen he dedicated the new National Institutes of Health
(NIH) Bethesda campus in October 1940, President
Franklin D. Roosevelt declared, “We cannot be a strong
nation unless we are a healthy nation. And so we must recruit
knowledge and science in the service of national strength” (1).
Formore than 65 years, theNationalHeart, Lung, and Blood
Institute’s (NHLBI’s) core mission has been, and continues
to be, the generation and dissemination of knowledge
and science with the goal of securing a healthy nation (2).
Thirty-two years after Roosevelt’s NIH dedication, on
July 26, 1972, Elliot Richardson, the Secretary of the U.S.
Department of Health, Education, and Welfare, announced
the establishment of a “National Hypertension Program”
(3). The program planned a 4-step approach to include
agreement on standards and conditions for treatment,
education of health workers, public dissemination of infor-
mation, and research on the impact of the program on
healthcare delivery. Richardson appointed 2 committees:
one, the Hypertension Information and Education Advisory
Committee, was to focus on the knowledge of hypertension
and the communication of that knowledge, whereas the
other, the Interagency Working Group, was to focus on
exchange of information and coordination with the profes-
sional community.
In 1977, the NHLBI issued the ﬁrst of a number of clinical
practice guidelines (4) that would emerge from the National
High Blood Pressure Education Program, as well as from
other similar efforts such as the National Cholesterol
Education Program. The NHLBI guidelines have covered
a variety of topics, including, but not limited to, cholesterol,
blood pressure, asthma, and vonWillebrand disease (5). Over
the years, these groundbreaking health education initiatives
have successfully promoted marked increases in the public’s
awareness of cardiovascular disease risk factors and contrib-
uted to the major reductions in coronary heart disease
mortality observed during this period (6,7).
In the ensuing years, the landscapes surrounding the
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undergone profound changes. Many more effective strate-
gies are available for clinicians and patients to choose from,
and orders of magnitude more clinical evidence information
is available. The advent of the Internet and the proliferation
of mass media outlets provide the lay public with direct-to-
consumer access to a plethora of health information. Clinical
research sophistication has grown, as the “mega-trial” has
gone from being the exception to the norm. During this
period, the number and scope of governmental entities
engaged in providing guidance on clinical practice have also
changed substantially. Meanwhile, numerous organizations
outside government have developed expertise and experience
in developing guidelines. Indeed, a special working group of
the NHLBI’s Advisory Council (NHLBAC) (5) has noted
that nearly all NIH institutes and centers have elected to
limit engagement in guideline development to efforts
involving close collaboration with professional societies or
other external groups. In recent history, the NHLBI has
been the lone exception to this general NIH practice.
The world of clinical practice guidelines has undergone,
and continues to undergo, transformational changes since the
NHLBI started issuing guidelines as an adjunct to its health
education efforts over 35 years ago. As the number of
available guidelines provided by a variety of sources has
exploded, serious questions and controversies have arisen
about how guidelines should be developed, implemented,
and evaluated. Critics have noted that it is not a given that
clinical practice guidelines beneﬁt patients (8). Guideline
developers have been criticized for failing to adequately
control for conﬂicts of interest (9), for issuing guidelines of
variable quality (10), and for issuing contradictory guidelines
that leave clinicians feeling confused and vulnerable (11). Yet
the development of clinical practice guidelines leads to
invaluable beneﬁts for patients and clinicians: improved
outcomes due to better deployment of evidence-based strat-
egies, improved consistency of care, empowering information
for patients, improved public policy through attention drawn
to areas of importance to public health, assistance to clini-
cians who aim to keep their practices up to date, and guid-
ance for quality-improvement activities (8). Guidelines also
help researchers and research funders identify important
research gaps and set the stage for the iterative process of new
knowledge generation and advances in patient care (8).
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driver’s seat. Primary care generalists, specialists, and gov-
ernment agencies may each have limitations that impede
their effectiveness in leading the development of guidelines
(8). These concerns have led many organizations to actively
reach out to many stakeholders, as was the case in a cardio-
vascular guideline on risk assessment that one of us (M.S.L.)
helped write (12,13). When multiple stakeholders work
together, there is a much greater likelihood of high-quality
products, products that reﬂect diverse perspectives, philos-
ophies, and expertise.
In response to these and other concerns, the Institute of
Medicine (IOM) recently issued 2 reports, 1 on standards
for systematic reviews (14) and the other on development
of trustworthy guidelines (15). Reﬂecting the vastly
increased growth and complexity of scientiﬁc literature and
methods, the standards on systematic reviews cover a variety
of domains, including: 1) assembling expert teams with the
capacity to manage bias, conﬂicts of interest, and stake-
holder input; 2) identifying pressing clinical needs while
developing an optimal analytic framework; 3) developing
and following rigorous protocols that cover the search for
and assessment of evidence, as well as its synthesis; and 4)
preparing structured, user-friendly, peer-reviewed ﬁnal
reports (14). The standards on guidelines include a similar
focus on transparency, management of conﬂicts of interest,
team composition, effective articulation of recommenda-
tions, external review, and updating. The IOM standards
emphasize the importance of the intersection of guideline
development and systematic reviews: speciﬁcally, “Clinical
Practice Guideline developers should use systematic reviews
that meet standards, [and should interact with] the
systematic review team regarding the scope, approach, and
output of both processes” (15).
It is noteworthy that the IOM issued 2 separate reports,
1 on writing of systematic reviews (14) and 1 on develop-
ment of guidelines (15). The 2 activities are related, require
careful intersection and coordination, but nonetheless, are
distinct. In some respects, this distinction reﬂects the
composition and charges of the 2 committees that Secretary
Richardson appointed back in 1972. This important delin-
eation between the writing of systematic reviews and the
construction of clinical practice guidelines has been articu-
lated by others. For example, Clifton Gaus, an administrator
of the Agency for Health Care Policy and Research from
1994 to 1997, recalls that when he consulted stakeholders,
“Almost unanimously they said, ‘We don’t use your guide-
lines per se, but the synthesis of science you base them on is
invaluable to us in writing our own guidelines’ ” (16).
Today, June 19, 2013, after a public meeting of the
NHLBAC, we report the NHLBI's plans in the domain of
clinical practice guidelines. In recognition of the rapidly
changing landscape and the need for periodic re-evaluation
and updating of the Institute’s health education portfolio,
the NHLBI leadership appointed two special working
groups of the NHLBAC to provide guidance on optionsto optimize the Institute’s unique contribution to the
process of guideline development. The NHLBAC working
groups, which included members of the NHLBI Advisory
Council and Board of External Experts, engaged in exten-
sive processes that included consultation with a number of
internal and external stakeholders. The second working
group initiated the evaluation with 5 pending cardiovascular
disease–related documents focused on cholesterol, blood
pressure, risk assessment, lifestyle interventions, and
obesity.
The NHLBI is cognizant of the clear distinction between
the processes underlying the performance of systematic
reviews and the creation of practice guidelines. Both
NHLBAC working groups facilitated our evaluation of the
existing landscape and evolving best practices to deﬁne the
best approach for the NHLBI to fulﬁll its leadership role in
health education for the public. Accordingly, we plan to
refocus our health education agenda on our core mission of
knowledge generation and synthesis by supporting and
producing rigorous systematic reviews that can then be used
by other collaborating organizations to generate guideline
products that serve the public interest. The NHLBI has
decided that the 5 pending cardiovascular guideline products
will be published as evidentiary reviews, and that the Insti-
tute will subsequently collaborate with other organizations to
prepare and issue the related clinical practice guidelines.
We enthusiastically embrace this public service leadership
role in promoting health education by taking responsibility
for generating the systematic review dataset and evidence
syntheses that other organizations will use to develop
cardiovascular guidelines. Although the detailed elements of
the new NHLBI model remain to be further reﬁned, the
overall framework is well aligned with the IOM approach,
and our implementation plan will be governed by 6 oper-
ating principles:
1. Before taking on new evidence syntheses, the NHLBI
will consult closely with external stakeholders to
identify high-priority needs with compelling relevance
to the NHLBI mission and the health of the nation.
2. Once those needs are identiﬁed, the NHLBI will
work with external stakeholders to determine which
critical questions are most crucial for their ability to
generate guidelines that are reliable, robust, credible,
relatively easy to implement, and likely to promote
signiﬁcant improvements in public health.
3. In supporting and generating evidence syntheses, the
NHLBI will pay careful attention to the evolving
standards on systematic reviews promulgated by the
IOM and other credible sources (14).
4. In enabling partner organizations to generate their
own guideline products, the NHLBI will continue to
abide by the highest standards for developing trust-
worthy clinical practice guidelines and will continue to
adapt as best practices and the landscape of stake-
holders evolve (15).
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evaluation and continuous improvement in line with
our commitment to results-based accountability and
stewardship of public resources (17).
6. The syntheses will identify evidence gaps, which can
guide research investments in areas of importance to
public health.
History has taught us that there are very few immutable
practices in science or medicine; and the time has come for
a change in the NHLBI practice of generating clinical
guidelines. As we adapt to changing times and reﬁne the
focus of our health education efforts, we remain steadfastly
committed to fulﬁlling our mission by facilitating the ge-
neration of rigorous systematic evidentiary reviews in support
of the highest quality clinical practice guidelines worthy of the
public trust. This new collaborative partnership model of
guideline development will enable the NHLBI to “recruit
knowledge and science in the service of national strength” as
envisioned by President Roosevelt 73 years ago (1).
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